Hirano Yudai, Shinya Yuki, Umekawa Motoyuki, Hasegawa Hirotaka, Kawashima Mariko, Wipplinger Christoph, Wipplinger Tamara, Katano Atsuto, Saito Nobuhito
Department of Neurosurgery, The University of Tokyo Hospital, Tokyo, 113-8655, Japan.
Department of Neurologic Surgery, Mayo Clinic, Rochester, MN, 55901, USA.
Neurosurg Rev. 2025 Jan 15;48(1):49. doi: 10.1007/s10143-025-03199-5.
Recent technologic advancements have facilitated the use of hypofractionated Gamma Knife-based radiosurgery (HF-GKRS) to treat large lesions or those in eloquent areas. This study aimed to analyze the preliminary results of HF-GKRS for these meningiomas, and to determine its effectiveness and safety. This single-center retrospective study analyzed data of patients who underwent HF-GKRS for large meningiomas or those in eloquent areas with > 6 months of follow-up. The primary outcome was progression-free survival (PFS). The secondary outcomes were neurological deterioration, post-treatment T2 signal changes following HF-GKRS, and tumor volume changes. Volumetric analysis of the tumors after treatment was also performed to assess changes in tumor size after HF-GKRS. Overall, 24 patients with a median follow-up period of 22 months (range: 6-49 months) were included. Among them, 18 (75%) patients had tumors in close proximity to the optic pathway, and 15 (63%) patients had large lesions (> 10 cm). The cumulative 1- and 3-year PFS rates were 100% and 92%, respectively. The cumulative 3-year rate of adverse radiation effects was 9%. Overall, 12 patients (50%) showed tumor reduction, with a median tumor reduction rate of 45% (range: 25-58%). Our preliminary results revealed that HF-GKRS for large meningiomas or those in eloquent areas is safe and effective, with satisfactory short- and mid-term PFS and low adverse radiation effects. Further research with more patients and longer follow-up periods is required.
最近的技术进步促进了基于伽玛刀的大分割放射外科手术(HF-GKRS)在治疗大病变或位于功能区的病变中的应用。本研究旨在分析HF-GKRS治疗这些脑膜瘤的初步结果,并确定其有效性和安全性。这项单中心回顾性研究分析了接受HF-GKRS治疗大脑膜瘤或位于功能区且随访时间超过6个月的患者的数据。主要结局是无进展生存期(PFS)。次要结局包括神经功能恶化、HF-GKRS治疗后T2信号变化以及肿瘤体积变化。还对治疗后的肿瘤进行了体积分析,以评估HF-GKRS后肿瘤大小的变化。总体而言,纳入了24例患者,中位随访期为22个月(范围:6 - 49个月)。其中,18例(75%)患者的肿瘤紧邻视路,15例(63%)患者有大病变(>10 cm)。1年和3年的累积PFS率分别为100%和92%。累积3年的不良放射效应发生率为9%。总体而言,12例患者(50%)肿瘤缩小,中位肿瘤缩小率为45%(范围:25% - 58%)。我们的初步结果显示,HF-GKRS治疗大脑膜瘤或位于功能区的脑膜瘤是安全有效的,短期和中期PFS令人满意,不良放射效应较低。需要对更多患者进行更长随访期的进一步研究。